AI Article Synopsis
- Several case reports indicate that patients with IgD multiple myeloma (MM) may successfully stop hemodialysis, although specific predictive factors have not been established.
- A 57-year-old Japanese woman with renal issues from IgD-λ multiple myeloma underwent bortezomib-based chemotherapy and was able to withdraw from hemodialysis after 50 days.
- This review suggests that younger age and starting bortezomib-based treatment early could be key indicators for successfully stopping hemodialysis in similar patients.
Article Abstract
Several previous case reports have shown that patients with immunoglobulin D (IgD) multiple myeloma (MM) can be withdrawn from hemodialysis, however, the characteristics that can predict withdrawal in these patients have not yet been elucidated. A 57-year-old Japanese woman required hemodialysis because of renal dysfunction due to IgD-λ and Bence Jones protein-λ MM. Bortezomib-based chemotherapy nine days after admission led to her withdrawal from hemodialysis on Day 50. In our case-based review, younger age and early initiation of bortezomib-based chemotherapy emerged as possible predictors of successful hemodialysis withdrawal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18926/AMO/65154 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis.
Kidney Int Rep
January 2025
Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Introduction: Complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) have high risks for disease recurrence and allograft loss in transplant kidneys. Pegcetacoplan (targeted complement 3 [C3]/C3b inhibitor) may prevent excessive deposition of C3 and complement 5 [C5] breakdown products and associated renal damage.
Methods: NOBLE (NCT04572854) is a prospective, phase 2, multicenter, open-label, randomized controlled trial evaluating the efficacy and safety of pegcetacoplan in posttransplant patients with recurrent C3G or IC-MPGN.
An Observational Study of the First 100 Patients Undergoing Nocturnal Every-Other-Day Online Hemodiafiltration: Clinical Outcomes and Patient and Technique Survival.
J Clin Med
January 2025
Nephrology and Renal Transplantation, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
: High-volume online hemodiafiltration (OL-HDF) has proven to be the most efficient dialysis modality and to offer better clinical outcomes in patients on hemodialysis. Longer and more frequent dialysis sessions have demonstrated clinical and survival benefits. : A single-center observational study of the first one hundred patients on nocturnal every-other-day OL-HDF was conducted with the aim of reporting the experience with this treatment schedule and evaluating analytical and clinical outcomes as well as the patient and technique survival.
View Article and Find Full Text PDFSensitization on Hemodialysis After Renal Graft Failure: HLA Incompatibility Still Matters.
Transplant Proc
January 2025
Department of Nephrology, Reina Sofía University Hospital, Cordoba, Spain.
Patients with renal graft failure can develop human leukocyte antigen (HLA) sensitization when returning to dialysis. There is no consensus on which factors could be associated with an increased risk of this kind of sensitization after graft loss. To try to identify some of these factors, a retrospective observational study was performed in our center.
View Article and Find Full Text PDFGraft Intolerance Syndrome Complicates Retransplantation.
Transplant Proc
January 2025
Doctor Peset University Hospital, Valencia, Spain; The Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (Fisabio), Valencia, Spain; University of Valencia, Valencia, Spain.
Background: Patients with non-functioning renal grafts constitute approximately 4% of patients with incident dialysis. Complete withdrawal of immunosuppression has been associated with a higher risk of HLA sensitization and renal graft intolerance syndrome (GIS).
Methods: We conducted a retrospective observational study of 63 patients with renal graft failure (from January 2012 to December 2022).
Evaluation of effect of cooled haemodialysis on cognition in patients with end-stage kidney disease (ECHECKED) feasibility randomised controlled trial results.
BMC Nephrol
December 2024
Department of Old Age Psychiatry, Heartlands Hospital, Birmingham, B9 5SS, UK.
Background: Cognitive impairment is common in haemodialysis patients with no known beneficial interventions. Cooler dialysate slows brain white-matter changes, but its effect on cognition is unknown. This feasibility trial was performed to inform a fully-powered, randomised trial to assess this.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!